| Fri, Nov 13, 2009 |
| • |
Unique Strategy Generates Big Returns for Baupost
Indie Research (Fri, Nov 13)
|
| Tue, Nov 10, 2009 |
| • |
THERAVANCE INC Financials
EDGAR Online Financials (Tue, Nov 10)
|
| Thu, Nov 5, 2009 |
| • |
Theravance and Astellas Announce the Commercial Launch of VIBATIV(TM) (telavancin) in the United States
Marketwire (Thu, Nov 5)
|
| Wed, Nov 4, 2009 |
| • |
THERAVANCE INC Files SEC form 10-Q, Quarterly Report
EDGAR Online (Wed, Nov 4)
|
| Tue, Nov 3, 2009 |
| • |
Theravance to Present at the 18th Annual Credit Suisse Health Care Conference
Marketwire (Tue, Nov 3)
|
| Mon, Nov 2, 2009 |
| • |
Theravance Announces New Employment Inducement Award
Marketwire (Mon, Nov 2)
|
| Wed, Oct 28, 2009 |
| • |
Astellas and Theravance Announce Submission of Telavancin MAA for the Treatment of Nosocomial Pneumonia and Complicated Skin and Soft Tissue Infections in Europe
Marketwire (Wed, Oct 28)
|
| • |
THRX's Loss Wider Than Expected
Zacks.com (Wed, Oct 28)
|
| Tue, Oct 27, 2009 |
| • |
Theravance, Inc. Q3 2009 Earnings Call Transcript
at Seeking Alpha (Tue, Oct 27)
|
| • |
Theravance Third Quarter 2009 Financial Results Call scheduled for 5:00 pm ET today
Shareholder.com (Tue, Oct 27)
|
| • |
THERAVANCE INC Files SEC form 8-K, Results of Operations and Financial Condition
EDGAR Online (Tue, Oct 27)
|
| • |
Theravance Reports Third Quarter 2009 Financial Results
Marketwire (Tue, Oct 27)
|
| • |
UPDATE - Glaxo starts late-stage tests with "Son of Advair"
at Reuters (Tue, Oct 27)
|
| • |
GlaxoSmithKline and Theravance commence Phase III Horizon programme to develop a next-generation treatment for COPD
Marketwire (Tue, Oct 27)
|
| • |
Q3 2009 Theravance Inc. Earnings Release - After Market Close
CCBN (Tue, Oct 27)
|
| Mon, Oct 26, 2009 |
| • |
Theravance Earns Milestone Payment
Zacks.com (Mon, Oct 26)
|
| Thu, Oct 22, 2009 |
| • |
Theravance earns $20M milestone
at bizjournals.com (Thu, Oct 22)
|
| • |
Theravance Earns $20 Million Milestone Under Telavancin Collaboration Agreement
Marketwire (Thu, Oct 22)
|
| Tue, Oct 20, 2009 |
| • |
Neurogenic Orthostatic Hypotension Treatment Should Pass Phase III Trials: Catalyst For Biotech Stock Says Wedbush Morgan Analyst
Wall Street Transcript (Tue, Oct 20)
|
| Mon, Oct 19, 2009 |
| • |
Theravance to Report Third Quarter 2009 Financial Results on October 27, 2009
Marketwire (Mon, Oct 19)
|
| Older Headlines |
|
|
|
|
Help
0.03 (0.22%) 
Headlines
